Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PCI-27483 · 1 trial · 3 indications
Clinically meaningful toxicity adverse events will be defined in accordance with by CTCAE v3.0
| Arm | Type | Description |
|---|---|---|
| Gemcitabine | ACTIVE_COMPARATOR | Subjects receive Gemcitabine 1000 mg/m2 weekly intravenous infusion. |
| PCI-27483 + Gemcitabine | EXPERIMENTAL | Part A: Subjects received PCI-27483 0.8 mg/kg BID as initial dose and may be escalated to 1.2, and 1.5 mg/kg BID. At the same time, subjects received Gemcitabine 1000 mg/m2 weekly intravenous infusion. Part B: Subjects received the PCI-27483 at 1.2 mg/kg BID and Gemcitabine 1000 mg/m2 weekly intravenous infusion. |
| Name | Type | Description |
|---|---|---|
| PCI-27483 | DRUG | Part A: Closed to enrollment.Part B: Approximately 20 patients will be randomized to the control arm that will receive a standard regimen of gemcitabine and 20 patients will be randomized to the PCI-27483 arm and treated with both gemcitabine and PCI-27483. PCI-27483 will be administered as subcutaneous (SC) injections, nominally at a dosage of 1.2 mg/kg BID. Patients receiving PCI-27483 with a tumor response or stable disease at 12 weeks will have the option to continue PCI-27483 treatment until disease progression or the investigator considers the study treatment no longer tolerable. Treatment with gemcitabine may continue per standard of care. All evaluable patients will roll over into Part C at week 16 (Day 113±5). If 2 consecutive INRs at 2 hours postdose are \>3.50,a reduced dosage will be calculated. |
| Gemcitabine | DRUG | - |
Inclusion Criteria: 1. Men or women at least 18 years old 2. Body weight ≥ 40 and ≤ 100 kg. 3. Part A: Metastatic ductal adenocarcinoma of the pancreas diagnosed ≤ 4 months prior to enrollment. (Locally advanced does not have any criteria) 4. Part B: Locally advanced ductal adenocarcinoma of the pa...
Top 20 of 68 competitors
PCI-27483 is an investigational small molecule being studied for the treatment of pancreatic cancer, specifically in patients with ductal adenocarcinoma and exocrine pancreatic cancer. It is being evaluated in combination with gemcitabine chemotherapy. The drug is in Phase 2 clinical development and is not yet approved by regulatory authorities.
PCI-27483 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. AbbVie is conducting clinical research on this investigational oncology drug for pancreatic cancer.
PCI-27483 is in Phase 2 clinical development. A Phase 2 study of the drug has been completed in patients with pancreatic cancer. The drug remains investigational and has not been approved for commercial use.
PCI-27483 has been studied in a completed Phase 2 clinical trial identified as NCT01020006. This trial evaluated the safety and tolerability of PCI-27483 in patients with pancreatic cancer who were receiving treatment with gemcitabine. The study enrolled 42 participants in the United States.
The completed Phase 2 trial of PCI-27483 was a randomized, active-controlled study. It did not use a double-blind design and did not select patients based on biomarkers. The trial enrolled adult patients of all sexes aged 18 years and older.